Recently, monotherapies of immune checkpoint inhibitor have been approved for some malignant tumors such as advanced melanoma, non-small cell lung cancer, renal cell cancer, Hodgkin lymphoma, head and neck cancer in Japan. As the next step, to aim improvement of the clinical benefit, development of combination immunotherapies including immune checkpoint inhibitors are ongoing. In this chapter, recent strategies of clinical development of combination immunotherapy are described.
Gan to kagaku ryoho. Cancer & chemotherapy. 2017 Sep [Epub]
Shigehisa Kitano
Dept. of Experimental Therapeutics, National Cancer Center Hospital.